PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Both companies show declining cash positions (-9.09% vs CRVO's -30.50%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Below half of CRVO's -30.50%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Other current assets growth < half of CRVO's -79.34%. David Dodd sees a leaner approach to short-term items.
-10.41%
Below half of CRVO's -24.54%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.27%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Both CRVO and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Below half of CRVO's -23.30%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.64%
Less than half of CRVO's -42.75%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of CRVO's 233.14%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Less than half of CRVO's 68.17%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Less than half of CRVO's 68.17%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Below half CRVO's 65.69%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
0.5-0.75x CRVO's -32.72%. Martin Whitman is wary of lagging equity growth vs. competitor.
-10.20%
Below half CRVO's -23.30%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.98%
Higher Total Investments Growth compared to CRVO's zero value, indicating better performance.
-5.39%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
9.19%
Less than half of CRVO's 30.50%. David Dodd sees better deleveraging or stronger cash buildup than competitor.